Dr. Mark Ware

Chief Medical Officer

Canopy Growth

Since joining Canopy Growth in July 2018, Dr. Ware has helped establish the Company’s global medical division, Spectrum Therapeutics and led the team responsible for supply and regulatory documentation, clinical development, medical affairs and global product safety. As CMO, Dr. Ware advises on scientific and ethical aspects of Canopy Growth’s global research efforts and is responsible for the Company’s pharmacovigilance safety program encompassing all R&D and commercial activities.

 

Prior to joining Canopy Growth, Dr. Ware was tenured associate professor in the Faculty of Medicine at McGill University. Following undergraduate studies in biochemistry and philosophy at Queen’s University, he obtained his medical degree at the University of the West Indies, undertook postgraduate training in internal medicine and secured a Master’s degree in epidemiology from the London School of Hygeine and Tropical Medicine. He began evaluating the role of cannabis in pain management at McGill University in 1999, where he served as Director of Clinical Research of the Alan Edwards Pain Management Unit at the McGill University Health Centre for over 10 years. He was cofounder of the non-profit Canadian Consortium for the Investigation of Cannabinoids and served as Executive Director from 2007 to 2018. He has advised the Canadian federal government on cannabis policy since 2001, and 2016, he served as the vice chair of the Federal Task Force on the Legalization and Regulation of Cannabis in Canada. He has over 100 publications on cannabis and pain in peer-reviewed journals and has spoken widely and national and international conferences on cannabis in medicine.


All Sessions by Dr. Mark Ware

Printer Friendly See Full Agenda

Day 1: Oct 6, 2020

Day 2: Oct 7, 2020

Day 3: Oct 8, 2020

1:50 pm

1:50 pm

Panel Discussion

Improve Your Assessment of the Medical Cannabis Market with the Latest Pharmacoeconomics and Health Canada Policy Developments for Pharmacies

The use of medical cannabis has continued to increase in tandem with greater knowledge concerning its effectiveness in treating various disorders.  Decisions regarding whether your organization should include it in your pipeline or formulary need to be backed by an evidence-based approach.  Discover the latest developments in the use of medical cannabis to assist you to:

  • Better understand the opportunities this market represents and evaluate whether the benefits of entering it outweigh the risks of staying out
  • Assess the growing body of evidence that supports the use of medical cannabis especially among older patients
  • Gain insight into how Health Canada is moving forward with policies for cannabis products in pharmacies

Benefit your organization with an evidence-based approach to decisions on medical cannabis